Copyright
©2014 Baishideng Publishing Group Inc.
World J Meta-Anal. Nov 26, 2014; 2(4): 135-153
Published online Nov 26, 2014. doi: 10.13105/wjma.v2.i4.135
Published online Nov 26, 2014. doi: 10.13105/wjma.v2.i4.135
Figure 5 Short-term and long-term pharmacological treatment of obesity.
1Under investigation (clinical trials); 2Anti-obesity effects being investigated. 5-HT: 5-hidroxytryptamine; CB1R: Cannabinoid-1 receptors; DA: dopamine; FDA: United States Food and Drug Administration; GLP-1: Glucagon-like peptide 1; NE: Norepinephrine; OXM: Oxyntomodulin; PYY: Peptide tyrosine-tyrosine; POMC: Pro-opiomelanocortin; T2DM: Type 2 diabetes mellitus.
- Citation: Martins A, Morgado S, Morgado M. Anti-obesity drugs currently used and new compounds in clinical development. World J Meta-Anal 2014; 2(4): 135-153
- URL: https://www.wjgnet.com/2308-3840/full/v2/i4/135.htm
- DOI: https://dx.doi.org/10.13105/wjma.v2.i4.135